RT Journal Article
SR Electronic
T1 Genomic analysis of SARS-CoV-2 breakthrough infections from Varanasi, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.19.21262487
DO 10.1101/2021.09.19.21262487
A1 Lamuk Zaveri
A1 Royana Singh
A1 Priyoneel Basu
A1 Sofia Banu
A1 Payel Mukherjee
A1 Shani Vishwakarma
A1 Chetan Sahni
A1 Manpreet Kaur
A1 Nitish Kumar Singh
A1 Abhay Kumar Yadav
A1 Ajay Kumar Yadav
A1 Ashish
A1 Shivani Mishra
A1 Shivam Tiwari
A1 Surendra Pratap Mishra
A1 Amareshwar Vodapalli
A1 Himasri Bollu
A1 Debashruti Das
A1 Prajjval Pratap Singh
A1 Gyaneshwer Chaubey
A1 Divya Tej Sowpati
A1 Karthik Bharadwaj Tallapaka
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.19.21262487.abstract
AB Studies worldwide have shown that the available vaccines are highly effective against SARS-CoV-2. However, there are growing laboratory reports that the newer variants of concerns (VOCs e.g. Alpha, Beta, Delta etc) may evade vaccine induced defense. In addition to that, there are few ground reports on health workers having breakthrough infections. In order to understand VOC driven breakthrough infection we investigated 14 individuals who tested positive for SARS-CoV-2 after being administered a single or double dose of Covishield (ChAdOx1, Serum Institute of India) from the city of Varanasi, which is located in the Indian state of Uttar Pradesh. Genomic analysis revealed that 78.6% (11/14) of the patients were infected with the B.1.617.2 (Delta) variant. Notably, the frequency (37%) of this variant in the region was significantly lower (p<0.01), suggesting that the vaccinated people were asymmetrically infected with the Delta variant. Most of the patients tested displayed mild symptoms, indicating that even a single dose of the vaccine can help in reducing the severity of the disease. However, more comprehensive epidemiological studies are required to understand the effectiveness of vaccines against the newer VOCs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a CSIR grant (MLP0128). GC is supported by Faculty IOE grant BHU (6031). RS is supported by funds from ICMR and DHR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is approved by the Institutional Ethics Committees of CSIR-CCMB and Banaras Hindu University, IndiaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequenced samples were deposited on GISAID. Accession IDs for submitted samples are available in Supplementary Table S1. Accession IDs for samples not sequenced in this study and used in data analysis are available in Supplementary Table S1.